Company Overview of CareDx, Inc
CareDx, Inc, a commercial stage company, develops, markets, and delivers diagnostic surveillance solutions for heart transplant recipients to help clinicians make personalized treatment decisions throughout a transplant patient’s lifetime. Its commercialized testing solution includes the AlloMap heart transplant molecular test (AlloMap), a blood-based test used to monitor heart transplant recipients for acute cellular rejection. The company markets its AlloMap solution to healthcare providers through its direct sales force that targets transplant centers and their physicians, coordinators, and nurse practitioners in the United States, Canada, and Europe. The company was formerly known as XDx...
3260 Bayshore Boulevard
Brisbane, CA 94005
Founded in 1998
Key Executives for CareDx, Inc
Chief Executive Officer, President and Director
Total Annual Compensation: $547.6K
Chief Medical Officer and Executive Vice President
Total Annual Compensation: $524.5K
Chief Compliance Officer and Chief Business Officer
Total Annual Compensation: $445.5K
Compensation as of Fiscal Year 2014.
CareDx, Inc Key Developments
CareDx, Inc Presents at The Leerink Partners 5th Annual Global Healthcare Conference, Feb-10-2016 09:15 AM
Jan 19 16
CareDx, Inc Presents at The Leerink Partners 5th Annual Global Healthcare Conference, Feb-10-2016 09:15 AM. Venue: The Waldorf Astoria, New York, New York, United States. Speakers: Peter Maag, Chief Executive Officer, President and Director.
CareDx and Diaxonhit Announce Completion of Technology Transfer of Allomap® Test in Europe
Jan 12 16
CareDx Inc. and Diaxonhit have announced the completion of the transfer of the CareDx proprietary AlloMap gene expression test into the Strasbourg University Hospital Central Immunology Laboratory (HUS) in France. This rigorous, multi-step validation process has demonstrated that AlloMap test results released from the HUS laboratory are equivalent to AlloMap results generated by the CareDx main laboratory in the United States. With the completion of this technology transfer, patient samples can now be tested at HUS. This transfer is a significant milestone for CareDx and its exclusive European licensee and commercial partner, Diaxonhit, which contracted with Strasbourg University Hospital in 2014 to be the dedicated testing laboratory for AlloMap throughout Europe. This technology transfer is the first of its kind, and was completed through a strong collaboration among commercial, technical and development teams at CareDx, Diaxonhit and HUS. Diaxonhit has utilized its expertise in transplantation to design health economic studies for AlloMap reimbursement in Europe. The French Ministry of Health has recently approved the funding of a study designed to demonstrate that AlloMap is non-inferior to biopsy to inform about the risk of acute cellular rejection among French heart transplant patients.
Allenex AB (publ), CareDx, Inc - M&A Call
Dec 16 15
To discuss acquisition of 78% of the outstanding shares of Allenex AB
Similar Private Companies By Industry
Recent Private Companies Transactions